A Phase 2 interventional study of Mesalamine and Probiotic in Diverticulitis, sponsored by Warner Chilcott. Completed at 36 sites in United States. Open to participants aged 35 Years to 85 Years. Per ClinicalTrials.gov, last updated 2013-04-22.
Sponsored by Warner Chilcott (part of AbbVie) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Diverticulitis with a site in United States — 3 open to participants now, 5 under way, none of them phase 3. Diverticulitis · United States.
Among the 33 studies in Diverticulitis with a site in United States, this one is the 9th largest by enrollment of the 20 interventional ones that give a count, is one of 6 that started in 2007, is one of 2 in phase 2, and was the 9th registered.
125 studies on the registry are indexed under Diverticulitis; 22 are open to participants now.
Browse Diverticulitis studies →3 of the 33 studies in Diverticulitis with a site in United States are open now. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18–90
True Bearing Diagnostics, Inc. · Sites in United States
Ages 7+ · Healthy volunteers
The Methodist Hospital Research Institute · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 16 Diverticulitis studies recruiting now, 10 (63%) set no upper age limit and 1 (6%) stops at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.
This study: 35 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 6 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 117 is close to the median of 120 across 63 interventional studies indexed under Diverticulitis.
Median enrollment 104 across the 20 interventional studies, 300 across the 13 observational. Of the 26 that completed or were terminated, 11 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 33 have an industry lead sponsor. The 10 most frequent:
This study is registered under Warner Chilcott, one of the names counted as AbbVie. Under that name alone:
Warner Chilcott is the lead sponsor of 58 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
AbbVie has 1 study filed under Diverticulitis — fewer than ten, so there is no comparison to draw.
2 of the studies in Diverticulitis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04095663University of WashingtonComparison of Surgery and Medicine on the Impact of Diverticulitis (COSMID) Trial | 2027-02-01 |
| NCT07579312True Bearing Diagnostics, Inc.Diagnosis of Abdominal Pain Using RNA Levels: The NATURAL Study | 2027-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 33 studies in Diverticulitis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether Asacol® 2.4 g/day (400 mg Mesalamine) is safe and effective in the treatment of diverticulitis.
This study is designed to evaluate the safety and efficacy of Asacol® 2.4 g/day in generally healthy, adult patients who have had an attack of acute diverticulitis. The study will evaluate the safety and efficacy of a 12 week treatment with Asacol® followed a 9 month non-treatment observation period in approximately 180 patients with acute diverticulitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Days 1 thru Days 10 to 14 (Visit 2): daily antibiotic therapy, dietary advice, and 6 placebo tablets (matching mesalamine) once a day. Visit 2 thru Week 12 : 1 placebo capsule (matching probiotic) and 6 placebo tablets (matching mesalamine) daily.
Drug: Placebo · Other: Dietary Advice · Drug: Antibiotic for Diverticulitis
Days 1 thru 10-14 (Visit 2): daily antibiotic therapy, dietary advice and 6 - 400 mg mesalamine tablets once a day. Visit 2 thru Week 12: 1 placebo capsule (matching probiotic) and 6 - 400 mg mesalamine tablets daily.
Drug: Mesalamine · Other: Dietary Advice · Drug: Antibiotic for Diverticulitis
Days 1 thru 10-14 (Visit 2): daily antibiotic therapy, dietary advice and 6 - 400 mg mesalamine tablets once daily. Visit 2 thru Week 12: 1- Bifidobacterium infantis 35624 capsule and 6 - 400 mg mesalamine tablets daily
Drug: Probiotic · Other: Dietary Advice · Drug: Antibiotic for Diverticulitis
6 - 400 mg tablets once daily
Once capsule daily Bifidobacterium infantis 35624 added at Visit 2 (Day 10 + 4 days)
Also known as: Align
6 placebo tablets for first 10 (+4) days followed by once daily placebo tablets.
Dietary advice
Physician recommended antibiotic for Diverticulitis taken for 10-14 days. Antibiotic not specified for study.
Global Symptom Score (GSS) at Week 12, Primary Efficacy Population
GSS - Abdominal Pain \& Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse).
Time frame: 12 Weeks
Percentage of Responders at Week 12 - ITT Population
Responder - patient whose GSS scores for all symptoms were either 0 or 1 GSS - Abdominal Pain \& Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse).
Time frame: 12 Weeks
Percentage of Responders at Week 52 - ITT Population
Responder - patient whose GSS scores for all symptoms were either 0 or 1 GSS - Abdominal Pain \& Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse).
Time frame: 52 Weeks
Change in GSS From Baseline to Week 12 - ITT Population
GSS - Abdominal Pain \& Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse).
Time frame: Baseline to Week 12
Change in GSS From Baseline to Week 52 - ITT Population
GSS - Abdominal Pain \& Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse).
Time frame: Baseline to Week 52
Withdrawal Due to Surgery for Diverticulitis, Percentage, ITT Population, Week 12
Time frame: 12 Weeks
Recurrent Diverticulitis, Percentage, ITT Population, Week 12
At least one report of recurrent diverticulitis since the last visit (prior to the Week 12 visit).
Time frame: 12 Weeks
Recurrent Diverticulitis, Percentage, ITT Population, Week 52
At least one report of recurrent diverticulitis since the last visit (prior to the Week 52 visit).
Time frame: 52 Weeks
First patient screened 6 Dec 2007
| Milestone | Placebo | Mesalamine | Mesalamine & Probiotic |
|---|---|---|---|
| Started | 41 | 40 | 36 |
| Completed | 29 | 32 | 27 |
| Not completed | 12 | 8 | 9 |
| Withdrew: Adverse event | 3 | 5 | 1 |
| Withdrew: Physician decision | 3 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 2 |
| Withdrew: Recurrent diverticulitis,surgery require | 1 | 2 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 4 | 1 | 4 |
| Milestone | Placebo | Mesalamine | Mesalamine & Probiotic |
|---|---|---|---|
| Started | 29 | 32 | 27 |
| Completed | 22 | 27 | 24 |
| Not completed | 7 | 5 | 3 |
| Withdrew: Lost to follow-up | 1 | 2 | 0 |
| Withdrew: Relapse | 2 | 1 | 1 |
| Withdrew: Withdrawal by subject | 4 | 2 | 2 |
GSS - Abdominal Pain \& Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse).
| Scores on a Scale | Placebo | Mesalamine | Mesalamine & Probiotic |
|---|---|---|---|
| Global Symptom Score (GSS) at Week 12, Primary Efficacy Population | 7.3 ± 1.30 | 4.4 ± 1.07 | 5.9 ± 1.16 |
Responder - patient whose GSS scores for all symptoms were either 0 or 1 GSS - Abdominal Pain \& Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse).
| Percentage of Participants | Placebo | Mesalamine | Mesalamine & Probiotic |
|---|---|---|---|
| Percentage of Responders at Week 12 - ITT Population | 41.4 | 62.5 | 48.1 |
Responder - patient whose GSS scores for all symptoms were either 0 or 1 GSS - Abdominal Pain \& Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse).
| Percentage of Participants | Placebo | Mesalamine | Mesalamine & Probiotic |
|---|---|---|---|
| Percentage of Responders at Week 52 - ITT Population | 50.0 | 66.7 | 29.2 |
GSS - Abdominal Pain \& Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse).
| Scores on a Scale | Placebo | Mesalamine | Mesalamine & Probiotic |
|---|---|---|---|
| Change in GSS From Baseline to Week 12 - ITT Population | -16.14 ± 2.082 | -17.63 ± 1.825 | -16.11 ± 2.110 |
GSS - Abdominal Pain \& Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse).
| Scores on a Scale | Placebo | Mesalamine | Mesalamine & Probiotic |
|---|---|---|---|
| Change in GSS From Baseline to Week 52 - ITT Population | -16.82 ± 2.527 | -17.30 ± 2.040 | -16.00 ± 1.931 |
| Percentage of Participants | Placebo | Mesalamine | Mesalamine & Probiotic |
|---|---|---|---|
| Withdrawal Due to Surgery for Diverticulitis, Percentage, ITT Population, Week 12 | 2.4 | 5.0 | 0.0 |
At least one report of recurrent diverticulitis since the last visit (prior to the Week 12 visit).
| Percentage of Participants | Placebo | Mesalamine | Mesalamine & Probiotic |
|---|---|---|---|
| Recurrent Diverticulitis, Percentage, ITT Population, Week 12 | 20.0 | 12.5 | 11.8 |
At least one report of recurrent diverticulitis since the last visit (prior to the Week 52 visit).
| Percentage of Participants | Placebo | Mesalamine | Mesalamine & Probiotic |
|---|---|---|---|
| Recurrent Diverticulitis, Percentage, ITT Population, Week 52 | 31.0 | 28.1 | 37.0 |
Collected over 6 Dec 2007 thru 1 Mar 2010. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 6/41 (14.6%) | 32/41 (78%) |
| Mesalamine | — | 5/40 (12.5%) | 37/40 (92.5%) |
| Mesalamine & Probiotic | — | 0/36 (0%) | 26/36 (72.2%) |
| Event | Placebo | Mesalamine | Mesalamine & Probiotic |
|---|---|---|---|
| DiverticulitisInfections and infestations | 2/41 | 0/40 | 0/36 |
| Atrioventricular BlockCardiac disorders | 1/29 | 0/32 | 0/27 |
| Benign Ovarian TumourNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/29 | 0/32 | 0/27 |
| Colon OperationSurgical and medical procedures | 1/29 | 0/32 | 0/27 |
| GastritisGastrointestinal disorders | 1/29 | 0/32 | 0/27 |
| SyncopeNervous system disorders | 1/29 | 0/32 | 0/27 |
| Arterial Thrombosis LimbVascular disorders | 0/29 | 1/32 | 0/27 |
| BronchopneumoniaInfections and infestations | 0/29 | 1/32 | 0/27 |
| Tendon RuptureInjury, poisoning and procedural complications | 0/29 | 1/32 | 0/27 |
| Vascular PseudoaneurysmInjury, poisoning and procedural complications | 0/29 | 1/32 | 0/27 |
| Event | Placebo | Mesalamine | Mesalamine & Probiotic |
|---|---|---|---|
| Abdominal PainGastrointestinal disorders | 1/41 | 12/40 | 4/36 |
| ConstipationGastrointestinal disorders | 5/41 | 3/40 | 3/36 |
| PyrexiaGeneral disorders | 3/29 | 1/32 | 2/27 |
| DiarrhoeaGastrointestinal disorders | 2/41 | 4/40 | 3/36 |
| NauseaGastrointestinal disorders | 4/41 | 1/40 | 1/36 |
| PainGeneral disorders | 0/41 | 0/40 | 3/36 |
| HaematocheziaGastrointestinal disorders | 0/41 | 3/40 | 0/36 |
| Upper Respiratory Tract InfectionInfections and infestations | 1/29 | 1/32 | 2/27 |
| Abdominal Pain LowerGastrointestinal disorders | 3/41 | 0/40 | 2/36 |
| Back PainMusculoskeletal and connective tissue disorders | 2/41 | 1/40 | 2/36 |
| Age, Customized(Participants) | Placebo | Mesalamine | Mesalamine & Probiotic | Total |
|---|---|---|---|---|
| < 65 years | 31 | 28 | 25 | 84 |
| >= 65 years | 10 | 12 | 11 | 33 |
| Sex: Female, Male(Participants) | Placebo | Mesalamine | Mesalamine & Probiotic | Total |
|---|---|---|---|---|
| Female | 19 | 23 | 19 | 61 |
| Male | 22 | 17 | 17 | 56 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Mesalamine | Mesalamine & Probiotic | Total |
|---|---|---|---|---|
| Hispanic or Latino | 4 | 2 | 4 | 10 |
| Not Hispanic or Latino | 37 | 38 | 32 | 107 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | Mesalamine | Mesalamine & Probiotic | Total |
|---|---|---|---|---|
| Caucasian | 39 | 39 | 33 | 111 |
| Black | 2 | 0 | 2 | 4 |
| Asian (Oriental) | 0 | 0 | 1 | 1 |
| Multi-racial | 0 | 1 | 0 | 1 |
| Region of Enrollment(participants) | Placebo | Mesalamine | Mesalamine & Probiotic | Total |
|---|---|---|---|---|
| United States | 41 | 40 | 36 | 117 |
The record gives a start of Nov 2007, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2011, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Mesalamine · Probiotic